Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized M скачать в хорошем качестве

Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized M

Speaker: Mark Titus, PhD, Associate Professor, Department of Genitourinary Medical Oncology Biography: Dr. Titus earned his Ph.D. from the University of Washington, Seattle Washington and completed his postdoctoral research in the Laboratories for Reproductive Biology, University of North Carolina School of Medicine at Chapel Hill, North Carolina. His initial faculty appointment was in the Department of Urology at Roswell Park Cancer Center, Buffalo NY. In 2012, Dr. Titus joined the faculty in Genitourinary Medical Oncology at MD Anderson Cancer Center. WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry Abstract: Androgen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Novel second generation enhanced androgen inhibitors, abiraterone acetate and enzalutamide, improve survival of CRPC patients following androgen deprivation therapy. However, a significant group of patients demonstrate primary resistance to these agents and other patients acquire resistance during therapy. The mechanisms of enhanced androgen inhibitor resistance are complex. AR-dependent mechanisms involve AR overexpression, AR mutation, intra-tumor ligand biosynthesis, modulation of co-activators and co-repressors and expression of AR spice variants. AR-independent tumors activate glucocorticoid receptor and differentiate to aggressive variant or neuroendocrine phenotype with loss of tumor suppressors. Patient derived xenografts (PDX) developed from men with AR-positive or AR-negative CRPC were used to determine impact of AR signaling on glycolysis. We used two AR positive (MDA-PCa-133 and 180-30) and 2 AR negative (MDA-PCa-144 and 155) PDX grown in intact male mice. In vivo hyperpolarized MRI of each PDX was performed at a tumor volume of ~1.0 cm3 using 1-[13C]-pyruvate conversion to 1-[13C]-lactate. Ex vivo measurement of glycolytic metabolites, lactate, tricarboxylic acids and unique cancer metabolites were determined using NMR and mass spectrometry. We found increased glycolysis and alterations in other bioenergy metabolites in AR-positive PDX models and in low androgen environment (castration) versus AR-negative models. Our research supports the potential of hyperpolarized metabolic imaging in determining the underlying biology and in vivo phenotyping of CRPC. SPONSORED BY: Agilent Technologies Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots https://www.labroots.com/ms/webinar/a... 2. Watch the webinar on YouTube or on the LabRoots Website https://www.labroots.com/ms/webinar/a... 3. Click Here to get your PACE credits: Expiration Date: December 05, 2019 06:00 AM http://www.labroots.com/credit/pace-c... LabRoots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc